The proteasome -- an emerging therapeutic target in cancer

Article Abstract:

A drug called bortezomib that inhibits proteasomes may be beneficial in patients with some types of cancer. This drug has already been approved by the FDA for treating multiple myeloma that has not responded to other chemotherapy drugs. The proteasome is a structure in all cells that breaks down proteins that are no longer needed.

Multiple myeloma

---

Producing penicillin

Article Abstract:

The meagerness of the supplies of penicillin dictated its slow evolution as a chemotherapeutic agent. In the fall of 1942, Charles Pfizer Company committed to the production of penicillin, and the supply problem was on its way to resolution.

Market information - general, Penicillin Preparations, Supply and demand, Penicillin, Penicillins

---

The price tag on progress - chemotherapy for colorectal cancer

Article Abstract:

The U.S. Food and Drug Administration (FDA) approved five new drugs for metastatic colorectal cancer. The cost of the drugs for an eight-week course will be $1.2 billion for an estimated 56,000 patients.

United States, Government regulation, Commodity & service prices, Prices and rates, Colorectal cancer, Licensing, certification and accreditation, Company pricing policy

Similar abstracts:

• Abstracts: The role of therapeutic antimicrobial mouthrinses in clinical practice: control of supragingival plaque and gingivitis
• Abstracts: Incremental treatment costs in National Cancer Institute-sponsored clinical trials. Pharmacy benefits and the use of drugs by the chronically III
• Abstracts: Improving the quality of care -- can we practice what we preach? Paying physicians for high-quality care

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.